Skip to main content
    R

    Recursion Pharmaceuticals Inc (RXRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.83
    -0.18 (-4.36%)

    Market Cap: $2.01B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(10/22)
    Avg Surprise
    -22.84%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.23
    Range$-0.25 - $-0.20
    6 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.23-0.2%
    60d ago$-0.23-0.2%
    30d ago$-0.23-0.7%
    7d ago$-0.23-0.7%
    Current$-0.23
    Revenue Consensus
    $13M
    Range$7M - $30M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.21
    Range$-0.27 - $-0.17
    7 analysts
    Revenue Consensus
    $-1972800
    Range$-14380510 - $31M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.21---
    Sep 26EST
    		-$-0.23---
    Jun 26
    Reported Aug 5
    		$-0.25$-0.23-8.70%Miss+39.0%
    Mar 26
    Reported May 6
    		$-0.22$-0.26+15.38%Beat+56.0%
    Dec 25
    Reported Feb 25
    		$-0.21$-0.30+30.00%Beat+60.4%
    Sep 25
    Reported Nov 5
    		$-0.36$-0.38+5.26%Beat-5.9%
    Jun 25
    Reported Aug 5
    		$-0.41$-0.35-17.14%Miss-2.5%
    Mar 25
    Reported May 5
    		$-0.50$-0.52+3.85%Beat-28.2%
    Dec 24
    Reported Feb 28
    		$-0.53$-0.42-27.16%Miss-26.2%
    Sep 24
    Reported Nov 6
    		$-0.34$-0.33-3.03%Miss+20.9%
    Jun 24
    Reported Aug 8
    		$-0.40$-0.38-5.26%Miss-5.3%
    Mar 24
    Reported May 9
    		$-0.39$-0.43+9.30%Beat-14.7%
    Dec 23
    Reported Feb 27
    		$-0.42$-0.45+6.67%Beat-40.0%
    Sep 23
    Reported Nov 9
    		$-0.43$-0.39-10.26%Miss-22.9%
    Jun 23
    Reported Aug 8
    		$-0.38$-0.37-2.70%Miss+0.0%
    Mar 23
    Reported May 8
    		$-0.34$-0.35+2.86%Beat-3.0%
    Dec 22
    Reported Feb 27
    		$-0.30$-0.24-25.00%Miss+21.1%
    Sep 22
    Reported Nov 8
    		$-0.35$-0.38+7.89%Beat-25.0%
    Jun 22
    Reported Aug 9
    		$-0.38$-0.37-2.70%Miss-22.6%
    Mar 22
    Reported May 10
    		$-0.33$0.10-430.00%Miss-43.5%
    Dec 21
    Reported Mar 23
    		$-0.38$-0.31-22.58%Miss-52.0%
    Sep 21
    Reported Nov 10
    		$-0.28$-0.28+0.00%Beat-
    Jun 21
    Reported Aug 13
    		$-0.31$-0.24-29.17%Miss-
    Mar 21
    Reported Apr 16
    		$-0.23$-0.23+0.00%Beat-
    Dec 20
    Reported Mar 3
    		$-0.25$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.69EV/EBITDAN/A
    Price/FCF-5.80xFCF Yield-17.25%
    Profitability
    Profit Margin0.00%Operating Margin-1760.00%
    ROE-56.60%ROIC-55.84%
    Financial Health
    Debt/Equity0.02xInterest CoverageN/A
    Current Ratio5.03xQuick Ratio5.03x
    Trading Statistics
    Beta1.03Avg Volume29.13M
    52-Week High$7.1852-Week Low$2.77

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.22
    SMA 20$3.99
    SMA 50$3.59
    SMA 200$3.57
    EMA 10$4.10
    EMA 20$3.98
    EMA 50$3.71
    EMA 200$3.74

    MACD

    Line: 0.17Signal: 0.21Hist: -0.03

    ADX

    ADX: 32.0+DI: 30.5-DI: 17.0

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down8.0
    PSAR$5.11

    Bollinger Bands

    Upper Band$4.71
    Lower Band$3.27
    %B Position3587%(Upper)
    Band Width0.39

    RSI (14-Day)

    Neutral
    49.0

    Momentum Oscillators

    Stoch %K29.0
    Stoch %D32.9
    Williams %R-85.8
    ROC (10d)-4.8%
    Momentum-0.20
    CCI (20d)-21.6
    MFI (14d)60.7

    Volatility Measures

    ATR (14d)$0.35(9.2%)
    StdDev (20d)0.36
    Hist Vol113.1%(High)

    Volume Flow

    VWAP$3.90
    OBV-394.1M
    AD Line-1.0B
    CMF (20d)0.088

    Volume Metrics

    Avg Vol (20d)30.6M
    Vol Ratio0.6x
    VWMA (20d)$4.13

    Pivot Points

    R3$4.74
    R2$4.55
    R1$4.28
    Pivot Point$4.09
    S1$3.83
    S2$3.64
    S3$3.37

    Advanced Oscillators

    TSI13.18
    Ultimate Osc48.0
    KST224.25

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$7.67M$6.47M$35.54M$5.17M$19.22M$14.74M$4.55M$26.08M$14.42M$13.79M$10.89M$10.53M
    Cost of Revenue$11.49M$12.49M$14.28M$14.69M$20.16M$21.83M$12.79M$12.08M$9.20M$11.17M$9.88M$10.88M
    Gross Profit$-3,821,000$-6,018,000$21.26M$-9,512,000$-938,000$-7,084,000$-8,248,000$14.00M$5.22M$2.63M$1.01M$-344,000
    Operating Expenses$131.15M$122.49M$129.60M$162.69M$175.29M$184.28M$175.52M$112.36M$105.76M$98.97M$99.94M$99.21M
    R&D$89.61M$87.90M$95.94M$121.06M$128.64M$129.63M$98.33M$74.60M$73.93M$67.56M$69.48M$70.01M
    SG&A$41.53M$34.59M$33.66M$41.63M$46.65M$54.65M$77.19M$37.76M$31.83M$31.41M$30.46M$29.20M
    Operating Income$-134,968,000$-128,505,000$-108,335,000$-172,202,000$-176,227,000$-191,368,000$-183,767,000$-98,354,000$-100,543,000$-96,340,000$-98,930,000$-99,550,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$11.28M$0$0$0$0$0$0
    Income Before Tax$-131,006,000$-122,108,000$-108,103,000$-162,250,000$-171,897,000$-202,645,000$-178,898,000$-95,675,000$-98,063,000$-92,152,000$-97,058,000$-93,017,000
    Income Tax Expense$-1,000$-4,604,000$19,000$3,000$0$-158,000$8,000$167,000$-523,000$-779,000$-4,062,000$0
    Net Income$-131,005,000$-117,504,000$-108,122,000$-162,253,000$-171,897,000$-202,487,000$-178,906,000$-95,842,000$-97,540,000$-91,373,000$-92,996,000$-93,017,000
    EBITDA$-112,839,000$-102,435,000$-88,625,000$-141,207,000$-148,048,000$-183,314,000$-165,947,000$-88,477,000$-89,095,000$-84,775,000$-89,505,000$-85,439,000
    EBIT$-131,006,000$-122,108,000$-108,103,000$-162,250,000$-171,897,000$-202,645,000$-178,898,000$-95,675,000$-98,063,000$-92,152,000$-97,058,000$-93,017,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RXRX

    News

    Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

    Recursion Pharmaceuticals, Inc. announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at $3.25 per share...

    mykxlg.com•10/15/26•Neutral

    Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

    Recursion Pharmaceuticals, Inc. announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at $3.25 per share...

    Yahoo! Finance Canada•10/15/26•Somewhat-Bullish

    A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX).

    Recursion Pharmaceuticals, Inc. director Robert Hershberg exercised options for 25,000 Class A common shares at $2.22 per share and subsequently sold those shares at $5.00 per share on October 6...

    Stock Titan•10/7/26•Somewhat-Bearish

    Under a trading plan, Recursion (RXRX) director sells 50,000 shares averaging $4.84 each.

    Recursion Pharmaceuticals (RXRX) director Blake Borgeson sold 50,000 shares of Class A common stock on October 6, 2026...

    Stock Titan•10/7/26•Bearish

    25,000 shares worth $125K are proposed for sale by Recursion (RXRX) director Robert Hershberg.

    Recursion Pharmaceuticals, Inc. director Robert M. Hershberg has filed a notice for a proposed sale of 25,000 Class A shares...

    Stock Titan•10/7/26•Neutral

    RXRX Valuation and Fair Value

    P/E
    -3.7x
    P/FCF
    -5.8x
    P/B
    2.2x
    See GNG's fair value

    RXRX Profitability: Margins, ROIC and FCF

    Gross margin
    3.5%
    Operating margin
    -1760.0%
    Net margin
    0.0%
    ROIC
    -55.8%
    ROE
    -56.6%
    FCF yield
    -17.3%

    RXRX Competitors

    CompanyTicker
    Butterfly Network IncBFLY
    Inspire Medical Systems IncINSP
    Fortrea Holdings Inc.FTRE
    Vera Therapeutics IncVERA
    Select Medical HoldingsSEM
    LeMaitre Vascular IncLMAT
    GeneDx Holdings Corp.WGS
    BioLife Solutions IncBLFS

    Sector: Healthcare

    RXRX Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    2
    Buy
    1
    Hold
    4
    Sell
    0
    Strong Sell
    0

    RXRX Bull Case vs Bear Case

    Bear case

    • RXRX's quarterly revenue changed -60.1% year over year.

    RXRX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -0.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.23
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About RXRX

    Does RXRX pay dividends?

    Recursion Pharmaceuticals Inc (RXRX) does not currently pay a regular dividend.

    What is RXRX's market cap?

    Recursion Pharmaceuticals Inc (RXRX) has a market capitalization of $2.01B with a current stock price of $3.83.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In